$LH

Wilkinson Peter J sold $439K of LH

Wilkinson Peter J (SVP, Chief Accounting Officer) sold 1,420 shares of LABCORP HOLDINGS INC. (LH) at an average of $309.23 ($309.22–$309.23, $0.44M total) across 2 trades on 2026-08-03.

Original reporting
SEC EDGAR · Wilkinson Peter J
Published Aug 5, 2026, 3:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 3:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
low confidence
Mentioned
$LH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The only new information is the specific open-market sale size, price range, and post-transaction holdings; it does not change LH’s operating outlook.

02

Market read

Traders may note insider selling, but there is no fundamental catalyst or guidance change tied to the filing.

03

What to watch

Insider sales are common and often not predictive; the disclosure lacks context on total holdings, compensation timing, or whether other insiders are buying.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-05 after-hours/late session window (per timestamp)

Background

The article is an SEC Form 4 insider transaction report for Labcorp Holdings (LH) by Peter J. Wilkinson, SVP and Chief Accounting Officer.

Company-level read

Ticker impact

$LHNeutralLow confidence
Context

SEC Form 4 shows LH CFO Wilkinson sold 1,420 shares in open-market trades at about $309.23 on 2026-08-03.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is an open-market sale, not a buy, and it does not include new company guidance, contracts, or regulatory actions.

Market effects

None.

None.

None.

Counterpoint

The sale may be driven by diversification or tax planning rather than a bearish view, especially without a 10b5-1 plan.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Wilkinson Peter J

    SVP, Chief Accounting Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.